TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Journal Title: 
Primary Author: 
Sallman DA
David A Sallman, Amy F McLemore, Amy L Aldrich, Rami S Komrokji, Kathy L McGraw, Abhishek Dhawan, Susan Geyer, Hsin-An Hou, Erika Adriana Eksioglu, Amy Sullivan, Sarah Warren, Kyle J MacBeth, Manja Meggendorfer, Torsten Haferlach, Steffen Boettcher, Benjamin L Ebert, Najla Al-Ali, Jeffrey E Lancet, John L Cleveland, Eric Padron, Alan F List
Original Publication Date: 
Thursday, July 30, 2020

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise pathogenetic mechanisms underlying these inferior outcomes have not been delineated. Here we characterize the immunological features of the malignant clone and alterations in the immune microenvironment in TP53 mutant and wild type MDS and sAML patients. Notably, PDL1 expression is significantly increased in hematopoietic stem cells of TP53 mutant patients, which is associated with MYC upregulation and marked down-regulation of MYC's negative regulator miR-34a, a p53 transcription target. Notably, TP53 mutant patients display significantly reduced numbers of bone marrow infiltrating OX40+ cytotoxic T-cells and helper T-cells, as well as decreased ICOS+ and 4-1BB+ NK cells. Further, highly immunosuppressive regulatory T-cells (i.e., ICOSHigh/PD-1neg) and MDSCs (PD-1low) are expanded in TP53 mutant cases. Finally, a higher proportion of bone marrow infiltrating ICOSHigh/PD-1neg Tregs is a highly significant independent predictor of overall survival. We conclude the microenvironment of TP53 mutant MDS and sAML has an immune privileged, evasive phenotype that may be a primary driver of poor outcomes, and submit that immunomodulatory therapeutic strategies may offer a benefit for this molecularly-defined subpopulation.